Mouse double minute 4 protein (MDM4, also known as Proto-oncogene protein mdmx) is a key negative regulator of the tumor suppressor p53. It shares structural similarity with its paralog Mouse double minute 2 (MDM2) but lacks intrinsic E3 ubiquitin ligase activity. Instead, it binds directly to p53, inhibiting its transcriptional activity under normal conditions. In response to DNA damage or genotoxic stress, post-translational modifications such as phosphorylation alter its function—allowing it together with MDM2—to promote stabilization and activation rather than degradation/inhibition of p53. Overexpression or amplification contributes significantly to oncogenesis by disabling one major cellular defense against malignant transformation.
Other names
Proto-oncogene protein mdmxMDMXDouble minute 4 proteinp53-binding protein Mdm4Mdm2-like p53-binding protein
02
Mechanism of action
Drugs targeting this molecule aim to inhibit the interaction between MDMX (and/or MDM2) with p53, thereby restoring or enhancing wild-type p53 function leading to cell cycle arrest or apoptosis in cancer cells with functional TP53.
03
Biological functions
Negative regulation of p53 tumor suppressor activity via direct binding and inhibition of transcriptional activationRegulation of cell cycle progression and apoptosis through modulation of p53 pathwayModulation of cellular response to DNA damage and genotoxic stress, including switching from negative to positive regulation of p53 under stress conditions
04
Disease associations
Cancer (frequently overexpressed in various human cancers, promoting tumorigenesis by inhibiting the tumor suppressor function of p53)
05
Safety considerations
Potential safety concerns include on-target toxicity due to excessive activation of wild-type p53 in normal tissues, which could lead to unwanted cell cycle arrest or apoptosis; hematologic toxicities have been observed with some dual inhibitors targeting both MDM2 and MDMX.
06
Interacting drugs
There are no approved drugs directly targeting MDMX/MDM4 in clinical use as of now. However, several experimental compounds and small molecules are being developed to disrupt the interaction between MDM2/MDMX and p53 for cancer therapy. Most clinically advanced drugs target both MDM2 and, less potently, MDMX.
07
Biomarkers
Overexpression or amplification of MDMX/MDM4 can serve as a biomarker for certain cancers where the inhibition or loss-of-function mutation in TP53 is not present but where wild-type TP53 is suppressed by high levels of its negative regulators.
Beyond the preview
Go deeper on Mouse double minute 4 protein (MDM4 (also known as MDMX)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mouse double minute 4 protein (MDM4 (also known as MDMX)).